Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]
In development
Reference number: GID-TA11385
Expected publication date: TBC
Please note that this appraisal has been scheduled back into the work programme to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early February 2025 when we will write to you about how you can get involved.